- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- January 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- January 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- January 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- July 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- September 2026
- 185 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- September 2026
- 196 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- September 2026
- 188 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- September 2026
- 184 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- September 2026
- 190 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- September 2026
- 188 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- September 2026
- 184 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- September 2026
- 185 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- September 2026
- 183 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- September 2026
- 189 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- September 2026
- 187 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- September 2026
- 182 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more